Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived MouseGlobeNewsWire · 3 days ago
Pulmatrix (NASDAQ:PULM) Share Price Breaks Below Fifty Day Moving Average – Here’s What HappenedDefense World · 5 days ago
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%Defense World · Sep 27, 2026
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting MitochondriaGlobeNewsWire · Sep 22, 2026
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on MergerPRNewsWire · Aug 13, 2026Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$2.00 | -$0.29 | Beat |
| May 15, 2026 | – | -$0.32 | |
| Feb 26, 2026 | – | -$0.25 | |
| Oct 16, 2025 | – | -$0.24 | |
| Aug 6, 2025 | – | -$0.42 | |
| May 15, 2025 | – | -$0.50 |